[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

$repl

Replimune's (REPL) price target raised by JPMorgan, predicting high approval chances for RP1 plus nivolumab. The stock is up XXXX% pre-market, with the FDA decision on RP1 + Opdivo set for July XX.

About $repl

Replimune Group Inc. (REPL) is a biotechnology company focused on the development of oncolytic immunotherapies for the treatment of cancer.

Engagements: XXXXX #

Engagements Line Chart
Engagements 24-Hour Chart Data
Current Value: XXXXX
Daily Average: XXXXX
1 Month: XXXXXXX -XX%
1-Year High: XXXXXX on 2025-05-21
1-Year Low: XXX on 2025-05-03

Social Network	X
Engagements	XXXXX

Mentions: XX #

Mentions Line Chart
Mentions 24-Hour Chart Data
Current Value: XX
Daily Average: XX
1 Week: XXX -XX%
1 Month: XXX +644%
1-Year High: XXX on 2025-06-28
1-Year Low: X on 2025-04-27

Social Network	X
Mentions	XXX

Creators: XX #

Creators Line Chart
Creators 24-Hour Chart Data
XX unique social accounts have posts mentioning $repl in the last XX hours which is no change from in the previous XX hours Daily Average: XX
1 Week: XXX -XX%
1 Month: XXX +1,103%
1-Year High: XXX on 2025-06-28
1-Year Low: X on 2025-04-27

The most influential creators that mention $repl in the last XX hours

Creator	Rank	Followers	Posts	Engagements
@BiopharmIQ	X	XXXXXX	X	XXXXX
@Fredbenz0	X	XXXXX	X	XXX

Sentiment: XXX% #

Sentiment Line Chart
Sentiment 24-Hour Chart Data
Current Value: XXX%
Daily Average: XX%
1 Month: XXX% no change
1-Year High: XXX% on 2025-04-27
1-Year Low: XX% on 2025-06-24

Most Supportive Themes

FDA Approval and Price Target: (60%) Positive sentiment around potential FDA approval of RP1 plus nivolumab and the potential for increased sales.
Breakout and Buy Zone Potential: (30%) Mentions of $REPL in conjunction with other stocks, indicating potential breakout setups and buy-zone potentials.

Most Critical Themes

Volatility and Trial Concerns: (10%) Concerns about the lack of a randomized trial for RP1 plus nivolumab and the potential for volatility.

Network engagement breakdown:

Network	Positive	%	Neutral	%	Negative	%
X	XXXXX	XX%	XXXXX	XX%	X	X%

Total	XXXXX	XX%	XXXXX	XX%	X	X%

Top assets mentioned In the posts about $repl in the last XX hours

GSK plc (GSK) Regeneron Pharmaceuticals Inc (REGN) SuperRare (RARE) MicroCloud Hologram Inc. (HOLO) Cipher Mining Inc. Common Stock (CIFR) Enovix Corporation Common Stock (ENVX) Advanced Micro Devices (AMD) DeFi Development Corp. (DFDV) JPMorgan Chase (JPM) Qilian International Holding Group Ltd. Class A Ordinary Shares (BGM)

Top topics mentioned In the posts about $repl in the last XX hours